Vivian Altmann1, Artur F Schumacher-Schuh2, Mariana Rieck1, Sidia M Callegari-Jacques3, Carlos R M Rieder2, Mara H Hutz1. 1. Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 2. Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 3. Departamento de Estatística, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Abstract
AIM: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. PATIENTS & METHODS: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed. RESULTS: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001). CONCLUSION: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.
AIM: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. PATIENTS & METHODS: A total of 224 Parkinson's diseasepatients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed. RESULTS: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001). CONCLUSION: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.
Authors: Amy R Dunn; Carlie A Hoffman; Kristen A Stout; Minagi Ozawa; Rohan K Dhamsania; Gary W Miller Journal: Brain Res Date: 2017-12-21 Impact factor: 3.252
Authors: Amy R Dunn; Kristen A Stout; Minagi Ozawa; Kelly M Lohr; Carlie A Hoffman; Alison I Bernstein; Yingjie Li; Minzheng Wang; Carmelo Sgobio; Namratha Sastry; Huaibin Cai; W Michael Caudle; Gary W Miller Journal: Proc Natl Acad Sci U S A Date: 2017-02-28 Impact factor: 11.205